Clinical ResultsCuris reported six objective responses, four complete responses, and two partial responses; three of the four complete responses lasted more than six months.
Drug DevelopmentCuris has been focusing on developing their IRAK4 inhibitor, emavusertib, in lymphoma and leukemia, highlighting their leading position in the IRAK4 space.
Regulatory ProgressCuris had successful meetings with the FDA and EMA, supporting a potential accelerated approval path for emavusertib in primary CNS lymphoma.